Asahi Kasei (3407) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
1 Nov, 2026Executive summary
FY2023 net sales rose 2.1% to ¥2,784.9bn and operating income increased 10.2% to ¥140.7bn; Homes and Health Care grew while Material faced weak demand and pricing pressure.
Net income attributable to owners recovered to ¥43.8bn from a ¥91.9bn loss; impairment and affiliate losses contributed to net income missing the February forecast.
Operating income exceeded the February forecast in every segment.
Financial highlights
Gross profit increased to ¥816.0bn from ¥773.8bn; operating margin improved to 5.1% from 4.7%.
EBITDA was ¥322.9bn, up 5.9%; EBITDA margin rose to 11.6% from 11.2%.
Ordinary income fell 25.5% to ¥90.1bn, including ¥38.1bn in equity losses of affiliates.
Operating cash flow was ¥295.3bn; free cash flow was ¥152.7bn, versus negative ¥122.8bn in FY2022.
Comprehensive income rose to ¥206.2bn from ¥25.2bn, including a ¥151.8bn positive foreign currency translation adjustment.
Outlook and guidance
FY2024 forecast: net sales ¥2,912.0bn (+4.6%), operating income ¥180.0bn (+27.9%), ordinary income ¥181.0bn (+100.8%) and net income attributable to owners ¥100.0bn (+128.3%).
FY2024 EBITDA forecast is ¥356.0bn, up 10.2%; EPS forecast is ¥72.14.
Full-year dividend forecast remains ¥36 per share.
Operating income growth is forecast across all segments, supported by gradual automotive, electronics and semiconductor recovery and continued growth in Homes and Health Care.
Latest events from Asahi Kasei
- H1 operating income rose 54%, lifting FY2026 guidance to ¥290bn.3407
Q2 2027 - Q1 2026 delivered double-digit sales and profit growth, with a strong outlook for the full year.3407
Q1 2027 - On track for ¥270 billion operating income in FY2027, driven by Healthcare and Electronics growth.3407
Corporate presentation - Record earnings growth driven by Pharmaceuticals, Electronics, and Healthcare, with strong FY 2026 outlook.3407
Q4 2026 - FY2027 operating income target of ¥270 billion is within reach, led by Healthcare and AI/semiconductors.3407
Investor presentation - Aicuris acquisition secures a robust infectious disease pipeline, accelerating pharma growth.3407
Acquisition presentation - Record operating income and net income growth, with an upwardly revised full-year forecast.3407
Q3 2026 - Net income up 10% YoY, full-year profit guidance raised, and dividend maintained.3407
Q2 2026 - Operating income rose but net income plunged on one-time and extraordinary losses; outlook and dividends improved.3407
Q1 2026